Sprycel for breast cancer

Dasatinib, also known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. There are several trials, two completed and several ongoing of this drug in breast cancer (http://clinicaltrials.gov/ct2/results?term=dasatinib+breast).
There are studies that show that it is effective alone or with doxorubicin and cusplatin in cell cultures. A phase I and pahse II trial reproted as poster adn abstract respectively suggest that it has modes efficacy in combination with capecitabine. More studies clearly need to be performed.

http://www.posters2view.com/sabcs08/viewp.php?nu=3118

G. Somlo, F. Atzori, L. Strauss, A. Rybicki, X. Wu, W. Gradishar, J. Specht;Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): Phase I study CA180004.J Clin Oncol 27:15s, 2009 (suppl; abstr 1012)

Tryfonopoulos, D., O'Donovan, N., Corkery, B., Clynes, M., Crown, J.
Activity of dasatinib with chemotherapy in triple-negative breast cancer cells
J Clin Oncol (Meeting Abstracts) 2009 27: e14605

Comments

[Personalized Cancer Treatment]

Thank you for this informative post, I started researching and reading more bout cancer after finding out cancer is genetic in my family. Really enjoyed reading it and would love to read more of your posts.